1.	Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2000.00, NCI-2009-01593, R01CA114218, FHCRC-2000.00, 8357, FHCRC-IR-6259, NCT00669669
2.	O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: NCI Protocol IDs: NCI-2012-02927, 3405, U01CA062502, R21CA115057, CASE-CWRU-3405, 7080, NCT00961220
3.	O6-Benzylguanine and Temozolomide in Combination With Genetically Modified Peripheral Blood Stem Cells in Newly Diagnosed Glioblastoma Multiforme Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: NCI Protocol IDs: CASE6307, NCI-2011-02566, 8274, CWRU-CASE-6307, NCT01269424
4.	Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 to 66 Sponsor: NCI, Other Protocol IDs: 2583.00, NCI-2012-03168, P30CA015704, NCT01769911